BACKGROUND: Disorders in the blood coagulation system are often associated with malignancy. Patients with colorectal cancer (CRC) have been shown to have abnormal data for various coagulation tests. METHODS: We retrospectively analyzed the relation between the preoperative plasma fibrinogen level and tumor recurrence in 569 patients with CRC who underwent curative surgical resection and were followed up without adjuvant chemotherapy. RESULTS: The plasma fibrinogen level showed a positive association with tumor recurrence, age, sex, T stage, and TNM classification. When divided with the median value, hyperfibrinogenemia is positively correlated with tumor recurrence, although it lost independence in the multivariate analysis. In the C-reactive protein (CRP)-negative population, hyperfibrinogenemia is independently correlated with tumor recurrence and recurrence-free survival. In contrast, hyperfibrinogenemia has no effect on recurrence in CRP-positive patients. CONCLUSIONS: Hyperfibrinogenemia is clinically relevant in tumor recurrence before a systemic inflammatory response and thus can be a useful predictor of recurrence in the preinflammatory stage of CRC.
BACKGROUND: Disorders in the blood coagulation system are often associated with malignancy. Patients with colorectal cancer (CRC) have been shown to have abnormal data for various coagulation tests. METHODS: We retrospectively analyzed the relation between the preoperative plasma fibrinogen level and tumor recurrence in 569 patients with CRC who underwent curative surgical resection and were followed up without adjuvant chemotherapy. RESULTS: The plasma fibrinogen level showed a positive association with tumor recurrence, age, sex, T stage, and TNM classification. When divided with the median value, hyperfibrinogenemia is positively correlated with tumor recurrence, although it lost independence in the multivariate analysis. In the C-reactive protein (CRP)-negative population, hyperfibrinogenemia is independently correlated with tumor recurrence and recurrence-free survival. In contrast, hyperfibrinogenemia has no effect on recurrence in CRP-positive patients. CONCLUSIONS: Hyperfibrinogenemia is clinically relevant in tumor recurrence before a systemic inflammatory response and thus can be a useful predictor of recurrence in the preinflammatory stage of CRC.
Authors: Joseph S Palumbo; Jill M Potter; Lisa S Kaplan; Kathryn Talmage; David G Jackson; Jay L Degen Journal: Cancer Res Date: 2002-12-01 Impact factor: 12.701
Authors: C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick; M H Veeder; J A Mailliard Journal: Ann Intern Med Date: 1995-03-01 Impact factor: 25.391
Authors: Robert Kleemann; Philippe P Gervois; Lars Verschuren; Bart Staels; Hans M G Princen; Teake Kooistra Journal: Blood Date: 2002-08-29 Impact factor: 22.113
Authors: Sang Eok Lee; Jun Ho Lee; Keun Won Ryu; Byung-Ho Nam; Soo Jeong Cho; Jong Yeul Lee; Chan Gyoo Kim; Il Ju Choi; Myeong-Cherl Kook; Sook Ryun Park; Young-Woo Kim Journal: J Gastric Cancer Date: 2012-06-27 Impact factor: 3.720
Authors: Paul Dowling; Valentina Palmerini; Michael Henry; Paula Meleady; Vincent Lynch; Jo Ballot; Giuseppe Gullo; John Crown; Michael Moriarty; Martin Clynes Journal: BBA Clin Date: 2014-09-16